Technical Analysis for TRDA - Entrada Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 14.05 | 1.22% | 0.17 |
Earnings due: May 10
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Stochastic Reached Overbought | Strength | 0.00% | |
| Upper Bollinger Band Walk | Strength | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| Gapped Down | Weakness | 0.00% | |
| MACD Bullish Centerline Cross | Bullish | 1.22% | |
| BB Squeeze Ended | Range Expansion | 1.22% | |
| Above Upper BB | Strength | 1.22% | |
| Gapped Up | Strength | 1.22% |
| Alert | Time |
|---|---|
| Rose Above Previous Day's High | about 14 hours ago |
| Up 2% | about 14 hours ago |
| Up 1% | about 14 hours ago |
| Gap Down Closed | about 14 hours ago |
| Reversed from Down | about 14 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/10/2024
Entrada Therapeutics, Inc. Description
Entrada Therapeutics is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicles (EEV™), to engage intracellular targets that have long been considered inaccessible and undruggable. The Company’s EEV therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues with an improved therapeutic index. Through its proprietary, highly versatile and modular EEV Platform, Entrada is building a robust development portfolio of oligonucleotide-, antibody- and enzyme-based programs for the potential treatment of neuromuscular disease, immunology, oncology and diseases of the central nervous system. The Company’s lead oligonucleotide programs include ENTR-601-44 targeting Duchenne muscular dystrophy (DMD), and a follow-on program targeting myotonic dystrophy type 1 (DM1).
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Disease Medical Genetics Dystrophy Muscular Dystrophy Duchenne Muscular Dystrophy Duchenne Myotonic Dystrophy Genetic Genealogy Neuromuscular Disease
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 18.44 |
| 52 Week Low | 10.8254 |
| Average Volume | 76,630 |
| 200-Day Moving Average | 14.51 |
| 50-Day Moving Average | 13.00 |
| 20-Day Moving Average | 12.85 |
| 10-Day Moving Average | 13.04 |
| Average True Range | 0.79 |
| RSI (14) | 59.68 |
| ADX | 16.95 |
| +DI | 24.42 |
| -DI | 13.62 |
| Chandelier Exit (Long, 3 ATRs) | 11.86 |
| Chandelier Exit (Short, 3 ATRs) | 14.19 |
| Upper Bollinger Bands | 14.07 |
| Lower Bollinger Band | 11.62 |
| Percent B (%b) | 0.99 |
| BandWidth | 19.13 |
| MACD Line | 0.13 |
| MACD Signal Line | -0.06 |
| MACD Histogram | 0.193 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 15.18 | ||||
| Resistance 3 (R3) | 15.12 | 14.68 | 14.99 | ||
| Resistance 2 (R2) | 14.68 | 14.39 | 14.71 | 14.93 | |
| Resistance 1 (R1) | 14.37 | 14.22 | 14.53 | 14.43 | 14.87 |
| Pivot Point | 13.93 | 13.93 | 14.01 | 13.96 | 13.93 |
| Support 1 (S1) | 13.61 | 13.64 | 13.77 | 13.67 | 13.23 |
| Support 2 (S2) | 13.17 | 13.46 | 13.20 | 13.17 | |
| Support 3 (S3) | 12.86 | 13.17 | 13.11 | ||
| Support 4 (S4) | 12.92 |
